PRME
Prime Medicine, Inc.
$3.99
+0.41
(+11.45%)
Mkt Cap
720.66M
Volume
8,066,435
52W Range
2.67-6.65
Sector
Healthcare
Beta
2.38
EPS (TTM)
-1.10 USD
P/E Ratio
-2.57
Revenue (TTM)
4.07M USD
Rev Growth (5Y)
-2.3%
EPS Growth (5Y)
N/A
Company Description
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 4.63M | 2.98M | 0 | 0 | 0 | 5.21M | 0 |
| Net Income | (201.14M) | (195.88M) | (198.13M) | (121.82M) | (165.37M) | (3.41M) | (2.53M) |
| EPS | -1.35 | -1.65 | -2.18 | -1.46 | -1.92 | -0.05 | -0.03 |
| Free Cash Flow | (167.09M) | (130.16M) | (174.14M) | (147.92M) | (38.23M) | (6.18M) | (1.33M) |
| FCF / Share | -1.12 | -1.10 | -1.91 | -1.52 | -0.40 | -0.06 | -0.01 |
| Operating CF | (162.56M) | (122.86M) | (165.41M) | (131.83M) | (34.08M) | (5.54M) | (1.33M) |
| Total Assets | 342.73M | 297.51M | 193.85M | 360.31M | 301.86M | 54.78M | 8.70M |
| Total Debt | 116.43M | 40.79M | 13.63M | 28.75M | 10.41M | 0 | 0 |
| Cash & Equiv | 63.03M | 182.48M | 41.57M | 187.62M | 185.42M | 36.98M | 8.65M |
| Book Value | 120.87M | 153.15M | 133.07M | 316.27M | 239.56M | 33.47M | 1.39M |
| Return on Equity | -1.66 | -1.28 | -1.49 | -0.39 | -0.69 | -0.10 | -1.82 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.15M | 856,000 | 838,000 | 1.23M | 1.11M | 1.45M | 2.18M | 209,000 | 0 | 591,000 | 0 | 0 |
| Net Income | (42.11M) | (49.12M) | (46.08M) | (50.58M) | (52.59M) | (51.89M) | (42.28M) | (52.52M) | (55.33M) | (45.76M) | (65.64M) | (50.71M) |
| EPS | -0.24 | -0.28 | -0.26 | -0.32 | -0.41 | -0.40 | -0.36 | -0.44 | -0.46 | -0.44 | -0.67 | -0.55 |
| Free Cash Flow | (41.09M) | (42.92M) | (37.55M) | (35.29M) | (42.98M) | (51.28M) | 14.45M | (27.19M) | (47.39M) | (70.03M) | (45.70M) | (42.08M) |
| FCF / Share | -0.23 | -0.24 | -0.25 | -0.22 | -0.33 | -0.39 | 0.12 | -0.23 | -0.40 | -0.67 | -0.47 | -0.46 |
| Operating CF | (41.05M) | (42.71M) | (37.26M) | (35.04M) | (41.41M) | (48.86M) | 16.25M | (25.91M) | (45.49M) | (67.71M) | (43.86M) | (39.17M) |
| Total Assets | 249.04M | 294.73M | 342.73M | 385.01M | 279.01M | 328.16M | 297.51M | 332.78M | 259.70M | 311.38M | 193.85M | 239.15M |
| Total Debt | 112.48M | 114.51M | 116.43M | 118.14M | 119.74M | 121.15M | 40.79M | 41.25M | 41.58M | 43.79M | 13.63M | 17.04M |
| Cash & Equiv | 47.45M | 64.11M | 63.03M | 71.40M | 53.80M | 91.88M | 182.48M | 117.98M | 55.60M | 94.16M | 41.57M | 43.96M |
| Book Value | 39.81M | 76.70M | 120.87M | 161.82M | 60.86M | 106.92M | 153.15M | 189.50M | 196.59M | 243.77M | 133.07M | 193.96M |
| Return on Equity | -1.06 | -0.64 | -0.38 | -0.31 | -0.86 | -0.49 | -0.28 | -0.28 | -0.28 | -0.19 | -0.49 | -0.26 |
PRME News
Leading Indicators For The October Breakout Cycle
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
Prime Medicine Gets FDA Green Light for Gene Editing Study
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Prime Drink Group Provides Bi-Weekly MCTO Status Report
Prime Medicine to Participate in Upcoming Investor Conferences
BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME
Prime Medicine: Soon In The Clinic
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates